Upgrade to SI Premium - Free Trial

Raymond James Reiterates Strong Buy Rating on Biohaven Pharma (BHVN)

October 8, 2026 9:50 AM
Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $30.00 price target on Biohaven Pharma (NYSE: BHVN).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments